Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 18, 2009
Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in VietnamC Flohr, L N Tuyen, R J Quinnell, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|November 19, 2003
Quantitative comparison of long-wavelength Alexa Fluor dyes to Cy dyes: fluorescence of the dyes and their bioconjugatesJudith E Berlier, Anca Rothe, Gayle Buller, et al.
JAMA Network Open|March 3, 2020
Effect of Pregnenolone vs Placebo on Self-reported Chronic Low Back Pain Among US Military Veterans: A Randomized Clinical TrialJennifer C Naylor, Jason D Kilts, Lawrence J Shampine, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 31, 2014
miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokinesYun Ji, Claudia Wrzesinski, Zhiya Yu, et al.
Nature Communications|May 16, 2019
miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fateYun Ji, Jessica Fioravanti, Wei Zhu, et al.
JCI Insight|June 15, 2017
In vivo kinetics and nonradioactive imaging of rapidly proliferating cells in graft-versus-host diseaseNataliya P Buxbaum, Donald E Farthing, Natella Maglakelidze, et al.
Nature Immunology|February 20, 2019
The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunitySanjivan Gautam, Jessica Fioravanti, Wei Zhu, et al.
Blood|September 24, 2013
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantationJames N Kochenderfer, Mark E Dudley, Robert O Carpenter, et al.
Cell|September 14, 2024
Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacyJeremy G Baldwin, Christoph Heuser-Loy, Tanmoy Saha, et al.
Signal Transduction and Targeted Therapy|August 8, 2024
LIM-domain-only 4 (LMO4) enhances CD8+ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signalingRoland C Schelker, Jessica Fioravanti, Fabio Mastrogiovanni, et al.
Pageof 11